HACKENSACK, N.J., July 28 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced that its Chairman, Dr. Arnold Lippa, and its new CEO and President, Dr. Les Hudson, will present at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference on Friday, July 29, 2005. Their presentations, scheduled to begin at 9:45 a.m. ET, will be webcast live from The Southampton Inn, Southampton, New York. Drs. Lippa and Hudson will provide an overview of the company’s corporate strategy and ongoing development programs.
The webcast of the presentation and Q&A session may be accessed through a link in the investor relations section of DOV’s website: http://www.dovpharm.com . Presentations will be archived and available after the conference for 90 days.
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system and other disorders, including cardiovascular, that involve alterations in neuronal processing. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain, anxiety, and depression. Our partner Neurocrine has filed two NDAs for the use of DOV’s compound indiplon for the treatment of insomnia.
DOV Pharmaceutical, Inc.
CONTACT: Barbara Duncan, Chief Financial Officer, or Alan Beckhard,Manager, Investor Relations and Corporate Communications, DOVPharmaceutical, Inc., +1-201-968-0980
Web site: http://www.dovpharm.com/